NPC Biomarkers

Posted On 2021-06-04 15:32:46



In this special series on “NPC Biomarkers”, we aim to provide an overview of conventional biomarkers used in NPC detection and monitoring as well as highlight several more recent novel approaches that might have value in NPC diagnosis and prognosis. The series is guest-edited by:
Professor Maria Li Lung, PhD, Department of Clinical Oncology, University of Hong Kong, Hong Kong (SAR), China
Professor Lawrence S. Young, PhD, DSc, FRSB, FRCPath, FRCP, FMedSci, Warwick Medical School, University of Warwick, Warwick, UK

Professor Lung is currently a Chair Professor at the University of Hong Kong, where she leads several multi-institutional multi-disciplinary group research efforts on cancer studies. Her main research interests are focused on elucidating the molecular genetic basis of cancers of importance in Chinese, namely nasopharyngeal carcinoma and esophageal carcinoma. Using molecular, functional and next-generation sequencing approaches, her studies seek to elucidate the genetic susceptibility and the tumor molecular landscape of germline and somatic genetic variants of importance in these cancers and their usefulness in patient stratification and treatment.

Professor Young is internationally recognized for his work on the role of virus infection (Epstein–Barr virus and human papillomavirus) in the pathogenesis of various tumours. He also has an interest in gene and immunotherapy and this work has resulted in a number of clinical trials. He has published over 230 research papers in scientific journals as well as over 75 reviews and book chapters in the fields of virology, cancer and tumour immunology.

Lawrence was Head of the Division of Cancer Studies at the University of Birmingham from 2001-2007 and was appointed as the inaugural Pro-Vice Chancellor and Head of the College of Medical and Dental Sciences at the University of Birmingham in 2008. Lawrence was appointed as a Pro-Vice Chancellor at the University of Warwick in January 2013 with responsibility for strategic planning and resources. In 2016 he became Vice-President at the University of Warwick, encompassing his existing responsibilities, while highlighting his leadership in the University’s engagement activities in China and Hong Kong. In 2018 Lawrence was appointed as Pro-Dean for External Affairs at Warwick Medical School and Director of the Warwick Cancer Research Centre. In 2019 Lawrence became co-lead of the new Warwick Health Global Research Priority (https://warwick.ac.uk/research/priorities/health/).

Series outline:

Introduction
1. NPC etiology and current challenges for diagnosis
Maria Li Lung, Department of Clinical Oncology, University of Hong Kong, Hong Kong (SAR), China

2. EBV and NPC carcinogenesis – an alternative viewpoint
Joseph TS Wee, Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore

Conventional Biomarkers and Their Use for Screening
3. EBV proteins as serological markers for NPC 
Anna Coghill, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

4. EBV-based NPC population screening
Mingfang Ji, Cancer Research Institute of Zhongshan, Zhongshan People's Hospital, Zhongshan, China

5. EBV ctDNA markers for NPC diagnosis and prognosis 
Dennis YM Lo, Department of Chemical Biology, Chinese University of Hong Kong, Hong Kong (SAR), China

6. miRNA Biomarkers for NPC Diagnosis and Prognosis
Fei Fei Liu, Department of Radiation Oncology, Princess Margaret Hotel, University of Toronto, Canada

7. NPC methylation biomarkers for NPC diagnostics
Qian Tao, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong (SAR), China

8. Prognostic value of EBV biomarkers for NPC staging and post-treatment surveillance 
Quynh-Thu Le, Department of Radiation Oncology, Stanford University, Stanford, CA, USA
Jacob A. Miller, Department of Radiation Oncology, Stanford University, Stanford, CA, USA

Novel Approaches for NPC
9. Clinical utility of circulating tumor cells for real-time monitoring of metastatic NPC patients
Josephine MY Ko, Department of Clinical Oncology, University of Hong Kong, Hong Kong (SAR), China

10. Measuring EBV-specific T cell responses in NPC
Rajiv Khanna, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia

11. Classifying the tumor microenvironment for NPC patient stratification
Musheng Zeng, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

Conclusion
12. Current and future of NPC diagnostics
Lawrence S Young, Warwick Medical School, University of Warwick, Warwick, UK

Disclosure:
The series “NPC Biomarkers” was commissioned by the editorial office, Annals of Nasopharynx Cancer without any sponsorship or funding. Maria Lung and Lawrence Young are serving as the unpaid Guest Editors for the series. Dr. Lung also serves as an unpaid editorial board member of Annals of Nasopharynx Cancer.